Veru Stock News

The stock price of Veru Inc (NASDAQ: VERU) is trading at over 20% pre-market. This is why it happened.

Veru Inc (NASDAQ: VERU) rises sharply after announcing positive efficacy and safety results from a Phase 2 trial evaluating VERU-111 versus placebo in approximately 40 hospitalized patients at h

– Potential for two-pronged action against COVID-19 as an antiviral and  anti-inflammatory agent supported by Phase 2 clinical study results –

Female Health Company The (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, to

After a stellar 3x rise since the March 23 levels of last year, at the current price of around $10 per share we believe Veru Inc. stock, a biopharmaceuticals company focused on oncology medicines, has

MIAMI, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, to

Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.

Shares of Veru Inc. soared 51.4% toward a seven-year high on massive volume, after the biopharmaceutical company announced positive results from a Phase 2 study of its treatment of breast cancer. Trad

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific u

Veru (VERU) stock is doing well on Monday after announcing positive news from a Phase 2 clinical trial of its breast cancer drug. The post VERU Stock News: 9 Things for Investors to Know About Veru Br

-- Phase 2 Multicenter, International Clinical Study Selected as Spotlight Presentation at 2020 San Antonio Breast Cancer Symposium –

-- Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium-- -- VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer

Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2020 Results - Earnings Call Transcript

-- Transformation to P remium O ncology B iopharmaceutical C ompany with L ate - S tage Clinical Drug P ipeline F ocused on P rostate and B reast C ancer is C omplete -- -- Company Poised to Initiate